CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SBI-101Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug88 AT-527 Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.24
D014947 Wounds and Injuries NIH 0.22

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.24

There is one clinical trial.

Clinical Trials

1 A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy

The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in COVID-19 subjects with Acute Kidney Injury (AKI). SBI-101 is a biologic/device combination product designed to regulate inflammation and promote repair of injured tissue using allogeneic human mesenchymal stromal cells. SBI-101 will be integrated into the renal replacement circuit and patients will be treated for up to 24 hours.

NCT04445220 COVID-19 Acute Kidney Injury Biological: SBI-101
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Measure: Safety and tolerability as measured by incidence of IP-related serious adverse events

Time: Outcomes and Serious Adverse Events through Day 180

Related HPO nodes (Using clinical trials)

HP:0001919: Acute kidney injury
Genes 29
STOX1 TCN2 DGKE SAA1 CFH LPIN1 CD46 C3 CD46 FLT1 CACNA1S CFB RYR1 CFH APRT HPRT1 HNF1B CCND1 CORIN CFHR1 HELLPAR CFI SLC26A1 THBD PYGM CFHR3 HNF4A CFI SLC22A12
Protein Mutations 0
SNP 0